ADMA Biologics
ADMA
$6.81
Share price
1.04%
Change (1 day)
99.12%
Change (1 year)
Categories
ADMA Biologics (ADMA) - Total liabilities
Total liabilities on the balance sheet as of December 2023 : $0.19 B
According to ADMA Biologics 's latest financial reports the company's total liabilities are $0.19 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
ADMA Biologics - Total liabilities on balance sheet (from 2010 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $0.19 B | -1.28% |
| 2022-12-31 | $0.19 B | 45.46% |
| 2021-12-31 | $0.13 B | 13.11% |
| 2020-12-31 | $0.11 B | 18.36% |
| 2019-12-31 | $0.10 B | 46% |
| 2018-12-31 | $69.1 M | 2.1% |
| 2017-12-31 | $67.68 M | 140.51% |
| 2016-12-31 | $28.14 M | 22.93% |
| 2015-12-31 | $22.89 M | 8.94% |
| 2014-12-31 | $21.01 M | 101.94% |
| 2013-12-31 | $10.4 M | 69.72% |
| 2012-12-31 | $6.13 M | |
| 2011-06-30 | $0 M | -20.55% |
| 2010-06-30 | $0.01 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Repligen
RGEN | $0.85 B | 339.85% | 🇺🇸 USA |
 Novavax NVAX | $2.51 B | 1,196.25% | 🇺🇸 USA |
 Cel-Sci
CVM | $16.06 M | -91.72% | 🇺🇸 USA |